logo

A Renewed Sense of Optimism In Paradigm Medical (OTC: PDMI.PK)
By: Michael Vlaicu   Tuesday, October 13, 2009 10:48 AM

Vote for next session
The next market session will close:

(Public, OTC:PDMI.PK)

The Medical device industry has been one of the most successful industries within 2008 and 2009, and 2010 should continue that trend. StocksHaven Investments profiles Paradigm Medical Industries, Inc., a promising company who will soon begin to introduce the first of its four new ophthalmic diagnostic devices, the Paravue, during the remainder of 2009. Plagued by lawsuits, financial woes, and poor management — the company has made a vast array of changes during late 2008 and 2009 leading to an invigorated interest in past and present shareholders. The company named Stephen Davis the new president, an individual with an impeccable ability to attain funds and grants for struggling institutions, alongside 20 years experience in the ophthalmic industry. Paradigm also has the only patented technology utilizing photon lasers for cataract removal and is poised to capture a niche market within the glaucoma and ultrasound microscopy fields. The glaucoma market alone is estimated to reach $4 billion in 2010. With a portfolio consisting of a total of 15 devices currently available, and 4 pending release with one expect by end of 2009, Paradigm seems to have positioned itself nicely for a rebound in the near future.

About Paradigm Medical Industries, Inc.

Paradigm Medical Industries, Inc. develops, manufactures, sources, markets and sells ophthalmic surgical and diagnostic instrumentation and related accessories, including disposable products. The Company's surgical equipment is designed for minimally invasive cataract treatment. Its cataract removal system, the Photon laser system, is a laser cataract surgery system designed to be marketed as the next generation of cataract removal. The Company's diagnostic products include a P2000 pachymetric analyzer, a P37 Ultrasonic A/B Scan, P40, P45 and P60 UBM Ultrasound Biomicroscopes, a P37 A/B Scan, two perimeters, the Blood Flow Analyzer, and the Glaid. The diagnostic ultrasonic products, including the P2000 pachymetric analyzer, the P37 Ultrasonic A/B Scan and the P40 UBM Ultrasound Biomicroscope were acquired from Humphrey Systems, a division of Carl Zeiss.

Products

P2700 A/B Scan

10 MHz A-Scan and 10 MHz B-Scan with 10 inch integrated monitor and foldup keyboard, making the P2700 very portable for moving from room to room. 8 image memory and optional printer available.  Product Details…

P37-II A/B Scan

10 MHZ A-Scan and 10 MHz B-Scan with a flat color monitor, integrated key board and trackball. High resolution imaging with precise biometry incorporating the necessary formulas.  Product Details…

P60 UBM

P60 Ultrasound BioMicroscope® provides sulcusâ€"to-sulcus imaging and three interchangeable probes including the new self-contained water path probe. Probe frequencies include 12.5 MHz, 20 MHz, 35 MHz, and 50 MHz. Available in single pulse frequency or  Product Details…

P37 A/B Scan

Ultrasound A and B Scan for precise biometry and high resolution retinal imaging. Designed for clinical application. Includes printer. Optional cart.  Product Details…

P40 Ultrasound BioMicroscope (UBM)

The Gold Standard in Ultrasound Biomicrosopy. The P40 Ultrasound BioMicroscope® provides a 50 MHz transducer frequency. Extreme high resolution ultrasound imaging with the resolution of a microscope.   Product Details…

P45 Ultrasound BioMicroscope (UBM)

The Gold Standard in a multi frequency UBM. Ultrasound BioMicroscope® with A and B Scan capabilities provided with a 10 MHz A Scan probe, a 10 MHz B Scan probe, and an 8 MHz diagnostic A Scan probe.

Next Page >>123

(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.
  
Advertisement
Popular Articles
Related Press Releases
Advertisement
Partner Center
Recent Articles by Michael Vlaicu



Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 500 contributors, press releases, SEC filings and full text news from more than four thousand sources.
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia